Ascentage Pharma Group International (AAPG)
NASDAQ: AAPG · Real-Time Price · USD
38.88
+2.12 (5.77%)
Jul 16, 2025, 12:32 PM - Market open
AAPG Revenue
In the year 2024, Ascentage Pharma Group International had annual revenue of 980.65M CNY with 341.77% growth. Ascentage Pharma Group International had revenue of 156.90M in the half year ending December 31, 2024, with 37.70% growth.
Revenue (ttm)
980.65M CNY
Revenue Growth
+341.77%
P/S Ratio
24.04
Revenue / Employee
1,729,541 CNY
Employees
567
Market Cap
3.23B undefined
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AAPG News
- 2 days ago - Ascentage Pharma Announces Pricing of Top-Up Placement - GlobeNewsWire
- 2 days ago - Ascentage Pharma Announces Proposed Top-Up Placement - GlobeNewsWire
- 6 days ago - Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL - GlobeNewsWire
- 8 days ago - Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance - GlobeNewsWire
- 4 weeks ago - EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL - GlobeNewsWire
- 5 weeks ago - Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress - GlobeNewsWire
- 6 weeks ago - Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report - GlobeNewsWire
- 6 weeks ago - Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - GlobeNewsWire